|
|
| (130 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | | | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| | + | *'''[[Clinical guidelines and advice]]''' |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| − | *'''[[Structure of covid19]]''' | + | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=32361692|t=2020. How the COVID-19 Overcomes the Battle? An Approach to Virus Structure |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[Diagnosis (Laboratory)]]''' |
| | | | |
| − | *'''[[Target binding and uptake]]'''
| |
| − | {{tp|p=32344526|t=2020. COVID-19 and RAS: Unravelling an Unclear Relationship |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | | | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| − | *'''[[Cytopathic effects]]'''
| |
| | | | |
| | + | |
| | + | |
| | + | *'''[[Structure of covid19]]''' |
| | + | |
| | + | |
| | + | *'''[[Target binding and uptake]]''' |
| | + | *'''[[Cytopathic effects]]''' |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Innate sensing]]''' | | *'''[[Innate sensing]]''' |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32360285|t=ä. Type I IFN immunoprofiling in COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32344056|t=ä. Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination |pdf=|usr=}}
| |
| − | {{tp|p=32333914|t=ä. A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| − | {{tp|p=32334118|t=ä. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32360286|t=2020. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32311489|t=ä. Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | ----
| + | *'''[[Pathobiology]]''' |
| | | | |
| | | | |
| − | *'''[[Early symptoms]]''' | + | *'''[[Disease Models]]''' |
| | | | |
| − | *'''[[Systemic disease, any manifestations]]'''
| |
| | | | |
| − | *'''[[Co-Infection]]''' | + | *'''[[Similar diseases and pathomechanisms]]''' |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| − | *'''[[Pulmonary embolism, coagulation]]'''
| |
| | | | |
| | | | |
| − | *'''[[Hematology]]''' | + | *'''[[Early symptoms]]''' |
| | | | |
| − | *'''[[Microvascular]]''' | + | *'''[[Systemic disease, any manifestations]]''' |
| | | | |
| − | *'''[[Heart]]''' | + | *'''[[Co-Infection]]''' |
| | | | |
| − | *'''[[Neurology, ophthalmology, orl]]'''
| |
| − | {{tp|p=32251791|t=2020. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 |pdf=|usr=}}
| |
| − | {{tp|p=32314322|t=ä. COVID-19 and the eye immunity: lesson learned from the past and possible new therapeutic insights |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Pulmonary embolism, coagulation]]''' |
| | | | |
| − | *'''[[Dermatology]]'''
| |
| | | | |
| − | *'''[[Gastroenterology, hepatology]]'''
| |
| | | | |
| − | *'''[[Kidney, urology]]'''
| |
| | | | |
| − | ----
| |
| | | | |
| | + | *'''[[Hematology]]''' |
| | | | |
| − | *'''[[Pathobiology]]'''
| |
| − | {{tp|p=32094336|t=2020. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa |pdf=|usr=}}
| |
| − | {{tp|p=32283245|t=ä. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Disease Models]]'''
| |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]''' | + | *'''[[Heart]]''' |
| − | ----
| + | |
| | | | |
| | | | |
| − | *'''[[Diagnosis (Laboratory)]]'''
| |
| − | {{tp|p=32300101|t=2020. Saliva: potential diagnostic value and transmission of 2019-nCoV |pdf=|usr=}}
| |
| − | {{tp|p=32286019|t=2020. Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Neurology, ophthalmology, orl]]''' |
| | | | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]'''
| |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | {{tp|p=32344326|t=2020. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Dermatology]]''' |
| | | | |
| − | *'''[[Respiration mgmt]]'''
| |
| − | {{tp|p=32251794|t=2020. Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?|pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Clinical guidelines and advice]]''' | + | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32361701|t=2020. COVID-19 Rapid Guideline in Kidney Transplant Recipients |pdf=|usr=}}
| + | |
| − | {{tp|p=32378816|t=2020. Clinical Insights and Management Recommendations for COVID-19 Patients Hospitalized in Internal Medicine Departments: Recommendations by the Corona Department Heads in Israel |pdf=|usr=}}
| + | |
| − | {{tp|p=32278795|t=ä. Creating Dermatology Guidelines for Covid-19: The Pitfalls of Applying Evidence Based Medicine to an Emerging Infectious Disease |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[Kidney, urology]]''' |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| | | | |
| | | | |
| | *'''[[Case reports]]''' | | *'''[[Case reports]]''' |
| − | {{tp|p=32269194|t=2020. Pneumonia Without Respiratory Symptoms |pdf=|usr=}}
| |
| − | {{tp|p=32361703|t=2020. Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *'''[[Case series]]'''
| |
| − | {{tp|p=32378815|t=2020. Clinical Characterization of 162 COVID-19 patients in Israel: Preliminary Report from a Large Tertiary Center |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Registries]]'''
| |
| − | {{tp|p=32305438|t=ä. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | ----
| + | *'''[[Case series]]''' |
| | | | |
| | | | |
| − | *'''[[Trials]]''' | + | *'''[[Registries]]''' |
| − | {{tp|p=32290293|t=2020. A Review of SARS-CoV-2 and the Ongoing Clinical Trials |pdf=|usr=}}
| + | |
| | | | |
| | + | |
| | + | *'''[[Trials]]''' |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| | | | |
| | | | |
| − | ----
| + | *'''[[Other routes of infection]]''' |
| | | | |
| | | | |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| − | {{tp|p=32340347|t=2020. Airborne Transmission Route of COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Other routes of infection]]'''
| |
| − | {{tp|p=32335340|t=ä. Potential Fecal Transmission of SARS-CoV-2: Current Evidence and Implications for Public Health |pdf=|usr=}}
| |
| − | {{tp|p=32278800|t=ä. Sexual transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A new possible route of infection?|pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Passive protective equipment]]''' |
| | | | |
| − | *'''[[Remission, recurrence and persistence]]'''
| |
| − | {{tp|p=32200109|t=2020. SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge |pdf=|usr=}}
| |
| − | {{tp|p=32251796|t=ä. The enlightenment from two cases of asymptomatic infection with SARS-CoV-2: is it safe after 14 days of isolation?|pdf=|usr=}}
| |
| − | {{tp|p=32147538|t=2020. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report |pdf=|usr=}}
| |
| | | | |
| − |
| |
| − | *'''[[Passive protective equipment]]'''
| |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32259628|t=ä. Clinician Wellness During the COVID-19 Pandemic: Extraordinary Times and Unusual Challenges for the Allergist/Immunologist |pdf=|usr=}}
| |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32360185|t=ä. Exercise and Fitness in the age of social distancing during the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | | | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32325710|t=2020. The COVID-19 Outbreak and Affected Countries Stock Markets Response |pdf=|usr=}}
| |
| − | {{tp|p=32305533|t=ä. The Socio-Economic Implications of the Coronavirus and COVID-19 Pandemic: A Review |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 179: |
Zeile 145: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32212099|t=ä. COVID-19 may transmit through aerosol |pdf=|usr=}}
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32225178|t=2020. The Impact of COVID-19 on Italy: A Lesson for the Future |pdf=|usr=}}
| |
| − | {{tp|p=32218558|t=2020. Preparedness and Lessons Learned from the Novel Coronavirus Disease |pdf=|usr=}}
| |
| − | {{tp|p=32271914|t=ä. The hearth of mathematical and statistical modelling during the Coronavirus pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32123989|t=ä. The novel coronavirus (SARS-CoV-2) infections in China: prevention, control and challenges |pdf=|usr=}}
| |
| − | {{tp|p=32219674|t=ä. Application of personal-oriented digital technology in preventing transmission of COVID-19, China |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Failure of politics and public health guidance]]''' | + | |
| | + | |
| | + | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | + | *'''[[Failure of politics and public health guidance]]''' |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32316647|t=2020. Using Social Media to Mine and Analyze Public Opinion Related to COVID-19 in China |pdf=|usr=}}
| + | |
| − | *[https://www.businessinsider.com/nearly-half-of-reopen-america-twitter-accounts-are-bots-report-2020-5?utmSource=twitter&utmContent=referral&utmTerm=topbar&referrer=twitter twitter botwar]
| + | |
| | | | |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| − | {{tp|p=32142979|t=2020. Li Wenliang, a face to the frontline healthcare worker The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak |pdf=|usr=}}
| |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − |
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − |
| |
| | | | |
| | | | |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| | | | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
